At present, there is no specific and effective antiviral therapy.In this study, an open, prospective/retrospective, randomized controlled cohort study was designed to compare the efficacy of different hormone doses in the treatment of 2019-nCoV severe Pneumonia.This study explores effective treatment programs for 2019-nCoV severe pneumonia and provides a reliable evidence-based basis for the treatment.
Drug: Methylprednisolone
Patients in the Group I will receive basic symptomatic supportive treatment,plus methylprednisolone(<40mg/d intravenous drip for 7 days).
Drug: Methylprednisolone
Patients in the Group II will receive basic symptomatic supportive treatment,plus methylprednisolone(40~80mg/d intravenous drip for 7 days).
Inclusion Criteria:
1.Meet the definition of severe pneumonia(Comply with any of the followings):
1. Shortness of breath,RR≥30 bpm;
2. In a resting state:SPO2≤93%;
3. PaO2/FiO2≤300mmHg.
2.2019-nCoV nucleic acid test was positive.
3.CT of the lung conformed to the manifestation of viral pneumonia.
Exclusion Criteria:
1. dying state (i.e. survival time is less than 24 hours);
2. progressive malignant tumor with life expectancy less than 6 months;
3. immunosuppressive status(patients using immunosuppressants or chemotherapeutic drugs)
4. underlying diseases requiring long-term glucocorticoid treatment in the past 6 months
or short-term glucocorticoid therapy in the past 4 weeks;
5. pregnancy
6. patients with glucocorticoid taboos
Department and Institute of Infectious Disease
Wuhan, Hubei, China
Investigator: Qin Ning, professor
qning@vip.sina.com
Qing Ning, Professor
+8613971521450
qning@vip.sina.com
Meifang Han, Professor
+8613986093605
mfhan@foxmail.com